Polypeptide With Localisation/Targeting Motif TRIZ Cases

Intranasal recombinant NEIL2 protein repairs transcribed genome lesions to reduce mortality from Klebsiella pneumoniae infection.

Weight-based CAR T cell dosing reduces toxicity risks while maintaining therapeutic response in pediatric patients.

A fusion peptide combines a transporter with a D-enantiomeric inhibitor to cross the cell membrane and block NMDAR interactions, resolving poor bioavailability.

Chimeric stimulatory receptors combine specific ectodomain and intracellular signaling domains to drive targeted T cell proliferation.

Segmented actin-based peptides with cell penetration domains resolve delivery complexity to modulate viral susceptibility.

Lectin-derived peptides bind tumor-associated carbohydrate antigens, recruiting immune cells while sparing normal tissue.

Mammalian expression systems produce glycosylated peptide receptive MHC-I complexes with native post-translational modifications.

Inhibiting mTOR activity during cultivation expands engineered T cells, reducing exhaustion to improve persistence.

Pre-assembling moieties through high-affinity hybridization accelerates reaction rates at low concentrations while ensuring stable final structures.

Distinct cis-regulatory regions in a single vector ensure stoichiometric co-expression, resolving silencing and recombination risks from duplicate sequences.

A carrier peptide fragment merges cell penetrating and nucleolar localization sequences to transport foreign substances into eukaryotic cells.

Tuning EpCAR affinity via CDR-H3 mutations spares healthy tissue and prevents T cell exhaustion.

Modified spike proteins target conserved S2 domains to elicit robust neutralizing antibodies, addressing rapid viral mutation challenges.

Redirecting T cell killing from PD-1 to PDIA3 overcomes resistance and extends survival in glioblastoma models.

GPI-anchored surface display eliminates enzyme removal complexity while enabling efficient post-translational modification of secreted recombinant proteins.

Anti-LAIR1 antibody blocks immunosuppressive signaling, reversing T cell suppression and restoring anti-tumor response in PD-1 resistant glioblastoma.

Engineered QTY Fc fusion proteins bind and remove excessive cytokines from blood, reducing cytokine release syndrome severity in CAR-T therapy.

EphrinB2-based CARs enhance cytotoxicity against neuroblastoma and osteosarcoma by leveraging specific ligand binding to overcome limited solid tumor efficacy.

A polyvalent DNA vaccine encodes consensus filovirus glycoproteins to elicit robust neutralizing antibodies and cytotoxic T lymphocyte responses.

N- and C-terminus mutations in the mutant peptide tag and catcher pair boost reaction rates up to 10-fold while maintaining thermal stability.

Single domain antibodies bind mesothelin with high affinity to enable targeted cancer diagnostics and therapy.

A phospholipid membrane anchors fucosyltransferase peptides to magnetic microparticles, enabling stable biomolecule immobilization.

A fusion protein directs donor DNA to replication origins, enhancing homology-directed repair efficiency.

Bivalent chimeric antigen receptors merge FLT3 and CD19 binding domains to prevent relapse caused by single antigen loss in leukemia treatment.

Specific mutations in TALE repeat units improve on-target binding while reducing off-target effects to ensure therapeutic safety.

Segmented reporter molecules with specific cleavage sites resolve indirect assay complexity to detect mitochondrial dysfunction.

Genetically modified effector cells express IL-10 inhibitors to block immunosuppression and enhance cytotoxicity against tumors.

Chimeric virus-like particles incorporate GPI-anchored GM-CSF and IL-4 conjugates to enhance systemic and mucosal immune responses.

Amino acid substitutions stabilize HMPV F trimers, resolving conformational instability that prevents robust immune responses.

Humanizing mouse CDRs reduces immunogenicity while maintaining binding affinity to mesothelin.

Engineered PIR1 signal peptides resolve variable native secretion efficiency and improve purification yield.

CRISPR-mediated FOXP1 ablation restores CD8+ T cell proliferation and anti-tumor activity against FSHR+ ovarian cancer.

Peptide inhibitors cross the blood brain barrier to inhibit LRRK2/PP1 interaction without causing toxicity.

Dual chimeric antigen receptors use a CD3ε intracellular signaling domain to maintain persistence and kill malignant cells despite antigen loss.

PC1-CTT polypeptides interact with nicotinamide nucleotide transhydrogenase to suppress cyst growth, avoiding liver injury from current vasopressin antagonists.

Gemcitabine modifies the immunosuppressive tumor microenvironment, enabling CAR-T cell infiltration and killing of solid tumors.

A chimeric antigen receptor targets SLAMF7 on malignant plasma cells to enable precise cancer cell elimination.

A fusion protein combining nCas9 fragments with deaminase domains enables precise base editing.

Knottin proteins paired with RNA destabilizing elements regulate CAR expression to reduce toxicity while maintaining long-term surveillance.

L2A5 monoclonal antibodies bind sialyl Tn and alpha-2,6-linked glycans to reduce off-target toxicity in cancer therapy.

Combining CAR-T cells with PD-1 and LAG3 antibodies enhances T cell persistence.

Recombinant vectors encode chimeric coronavirus spike proteins with modified transmembrane domains and proline substitutions to stabilize the prefusion conformation.

Segmented fusion proteins transform E6 and E7 structures to overcome insufficient antigen-specific immune response in cervical cancer treatment.

A multi-valent fusion protein binds EphA2, EphA3, and EphB2 receptors to deliver therapeutic agents directly to glioblastoma cells.

Merged CAR polypeptides target multiple glioblastoma antigens to overcome antigen escape heterogeneity.

Engineered T cells targeting FAP reduce pathological cardiac fibrosis and improve heart function.

Segmented CD163 decoys intercept viral binding while fusion with immunoglobulin Fc fragments extends protein half-life.

Optimized signal peptides enable recombinant strains to secrete beta-mannanase for konjac powder hydrolysis.

Mutant CD28 costimulatory domains in CAR T cells enhance Grb2 binding affinity to sustain prolonged immune responses against tumor targets.

Modified guide RNAs with inverted repeat sequences hybridize to spacer and complementary DNA strands, resisting removal by motor proteins.